NewsRoom Articles - Page 57 of 214

MondayOct 23, 2023 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine

Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may…

MondayOct 23, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients

Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis The study also revealed that the outer skin layers regained their normal appearance The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced…

FridayOct 20, 2023 3:20 pm

Scientists Find Potential to Reverse Prostate Cancer Treatment Resistance

Researchers say they may have found a new and more efficient means of treating prostate cancer that reverses the cancer’s resistance to treatment. Although treatment is fairly effective, prostate cancer can become resistant to treatment in some advanced cases and continue to grow despite low and even below-castrate level testosterone levels. Prostate cancer is the second most prevalent cancer type in American men after skin cancer, affecting around 288,300 men in the country and more than a million men globally every year. It has relatively favorable treatment outcomes, especially when the condition is diagnosed early. Many men have lived with…

ThursdayOct 19, 2023 1:06 pm

eCommerce Reshaping Consumer Healthcare Field, Report Says

E-commerce was born with the advent of the internet more than two decades ago, and it revolutionized business on a global scale. The internet opened an entirely new avenue for trade and granted companies access to a massively expanded market, allowing e-commerce to reach almost 19% of all global retail sales in 2022. Although digital health has been around for quite a while now, major e-commerce players such as Amazon and Walmart began making major investments in the healthcare sector in the wake of the coronavirus pandemic. The pandemic revealed that people are willing to seek medical help online if…

ThursdayOct 19, 2023 10:30 am

SOHM, Inc. (SHMN) Completes Acquisition of ABBIE Gene-editing Tech, Begins Preparations to Commercialize Solutions for Heart Disease

Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc. The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments The edited-gene cells are expected to be used for in-human clinical trials by 2025, using a non-viral vector for inserting the genes into patients’ bodies SOHM believes the technology will provide it with a competitive advantage in a market expected to grow…

WednesdayOct 18, 2023 1:42 pm

Sonobiopsy Promises Easier Way to Diagnose Brain Tumors

Current brain tumor diagnosis protocols usually involve magnetic resonance imaging (MRI) and computerized tomography (CT) scans followed by tissue biopsy or surgical resection. Although tissue biopsies are less invasive than surgical resection, both are relatively invasive procedures that involve invading the skull to access brain tumors in various ways. Patients who would like a less invasive procedure also have the option of blood-based liquid biopsies. This inexpensive technique involves running biomarkers through the blood to obtain genetic and molecular tumor information to help inform treatment decisions. However, blood-based liquid biopsies aren’t as effective at diagnosing brain tumors as biomarkers from…

TuesdayOct 17, 2023 2:40 pm

Researchers ID Biomarker That Could Improve Autoimmune Disease Treatment

New research from the VA Portland Health Care System and Oregon Health & Sciences University has identified a biomarker that can potentially improve autoimmune disease treatment outcomes. The research team investigated ankylosing spondylitis (AS), an inflammatory disease that causes vertebrae in the spine to fuse together over time, to understand the condition’s underlying molecular mechanisms. Also called axial spondyloarthritis, AS is a rare condition estimated to affect around 0.1-4.7% of the global population. It causes symptoms such as stooped posture, back pain, anemia, digestive illness, fatigue and weight loss. Scientists still don’t know the exact cause of the condition but…

TuesdayOct 17, 2023 9:00 am

SOHM, Inc. (SHMN) Bolsters Executive Team; Confident About Anticipated Developments and Opportunities

SOHM just announced the appointment of Wm. Dewey Rushing as the new VP-Quality His appointment follows the recent nomination of Dr. Krishna Bhat as the new Chief Medical Advisor and Dr. David Aguilar as the new COO It also follows the recently signed LOI for SOHM to acquire ABBIE stem cell disruptive technology and patents from CGA Intellectual Holdings Inc. SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the global nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market…

MondayOct 16, 2023 2:46 pm

Everything You Need to Know About Nonreactive Hep B Screening Results

An estimated 1.2 million people in the United States. and 350 million globally are infected with hepatitis B, a type of viral infection that attacks the liver. The condition is often characterized by symptoms such as dark urine, fever, appetite loss, abdominal pain, fatigue and weakness, jaundice and joint pain. Around 1% of hepatitis patients will develop fulminant hepatitis, a dangerous condition that can lead to liver failure and death while 5% of patients who develop hepatitis B in adulthood will develop chronic hepatitis B. However, the majority of hepatitis B patients can manage the condition through pharmaceuticals, eating a…

MondayOct 16, 2023 12:00 pm

PaxMedica Inc. (NASDAQ: PXMD) Announces Gold Sponsorship for The BRAIN Foundation’s Synchrony Symposia 2023

The BRAIN Foundation's Synchrony Symposia is the first and only international symposium on translational research for Autism Spectrum Disorder (“ASD”) PaxMedica Chairman and CEO Howard Weisman says that participating at the symposium is pivotal in advancing and fostering autism research As a Gold Sponsor, PaxMedica will have purview to the symposium’s interdisciplinary discussions, insights, and research presentations, clinical roundtables, mentor-mentee sessions, and more PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship…